Asthma biologics: anaphylaxis watch, injection schedules and no rescue role

What the biologics target

These drugs are monoclonal antibodies aimed at one step of airway inflammation. Omalizumab blocks IgE and is used in severe allergic asthma with raised IgE, with the dose set by weight and IgE level and given under the skin every two to four weeks. Mepolizumab, reslizumab and benralizumab block interleukin-5 or its receptor, which drives eosinophilic inflammation.

Dupilumab is another add-on for the eosinophilic type, and tezepelumab is an add-on for severe persistent asthma. Across the group, the aim is fewer exacerbations, fewer symptoms and less need for oral glucocorticoids. They are added to inhaled controller therapy rather than replacing it, so patients keep using their usual inhalers. Inhaler technique and adherence are still checked at each visit, because a biologic does not compensate for missed controller doses.

Observing for anaphylaxis

Omalizumab carries a boxed warning for anaphylaxis presenting as bronchospasm, hypotension, fainting, urticaria or swelling of the throat or tongue. It has occurred after the first dose and also more than a year into treatment. The label calls for starting therapy in a healthcare setting, observing patients after injections and being ready to manage anaphylaxis.

The MSD Manual notes anaphylaxis may follow any dose of dupilumab, benralizumab, omalizumab, tezepelumab or reslizumab, even after earlier doses were tolerated, and hypersensitivity reactions have occurred with mepolizumab. Before injecting, assess breathing and vital signs, have emergency drugs ready, observe for the set period and teach the signs to act on at home.

Not a rescue drug, and not a reason to stop steroids

Omalizumab is not indicated for acute bronchospasm or status asthmaticus, nor for emergency treatment of allergic reactions. Teach patients that the biologic works over weeks and months, and that during an attack they use the reliever inhaler and asthma action plan, seeking emergency care when symptoms are severe or not improving.

Corticosteroids are not stopped abruptly when a biologic starts. As oral steroids are reduced, MedlinePlus advises reporting extreme tiredness, weakness, abdominal or leg pain, dizziness, fainting, vomiting or low mood, which can signal that the body is not coping with the reduction. Other conditions such as eczema may also flare as steroid doses fall.

Schedules, infections and other monitoring

Keeping to the injection schedule matters because benefit builds over time. Missed-dose rules differ by product; for dupilumab, a dose more than seven days late is skipped and the usual schedule resumed. Record each injection date and site, and remind patients that benefit is judged over months, not after a single dose. Store prefilled syringes and pens as the label directs, and teach self-injecting patients to rotate sites.

Ask about worm infections before starting, since several labels address helminth infection. Mepolizumab has been linked to shingles, so zoster vaccination is recommended beforehand unless contraindicated. Patients on dupilumab should report eye problems and check before any vaccine. With omalizumab, fever, joint pain and rash resembling serum sickness are reasons to stop the drug.

Apply it to an exam-style scenario

Consider a hypothetical adult receiving a third omalizumab injection in clinic who, thirty minutes later, reports an itchy throat and hoarse voice, has hives, and has a lower blood pressure than at arrival. Options include sending her home with an oral antihistamine because earlier doses went well, giving her reliever inhaler and observing, or activating the emergency response.

Activating the emergency response and giving epinephrine per protocol is correct, because throat symptoms, hives and hypotension together suggest anaphylaxis. Previous tolerance does not rule it out, as the label notes reactions beyond the first dose. A reliever treats bronchospasm but not airway swelling or circulatory collapse.

Sources and further reading

DailyMed: Xolair (omalizumab) prescribing information. Boxed anaphylaxis warning and observation, not for acute bronchospasm or emergency allergy treatment, no abrupt steroid stop, eosinophilic conditions, serum sickness and helminth infection.

MSD Manual Professional: Pharmacologic treatment of asthma. Biologic targets and indications, omalizumab dosing basis, anaphylaxis after any dose and zoster vaccination before mepolizumab.

MedlinePlus: Mepolizumab injection. Monoclonal antibody class, shingles and worm infection history, and symptoms to report as oral steroids are reduced.